+ND Capital’s European Investment Strategy Delivers Again as Sale of CellPoint to Galapagos Paves the Way for Disruptive Point-of-Care Cell Therapy Model for Cancer Patients

Lausanne-based +ND Capital’s investment strategy delivers again as Galapagos acquires CellPoint for €125m cash upfront and up to €100m in milestone payments Potential for paradigm shift in CAR-T therapy with CellPoint’s decentralized point-of-care manufacturing model, in collaboration…